Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
- 31 August 2011
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (8), 773-784
- https://doi.org/10.1016/s1470-2045(11)70150-4
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBlood, 2011
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup StudyJournal of Clinical Oncology, 2010
- Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studiesAnnals of Oncology, 2010
- Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic SubtypesClinical Cancer Research, 2010
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA StudyJournal of Clinical Oncology, 2008
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2005
- Quality of life research within the EORTC—the EORTC QLQ-C30European Journal Of Cancer, 2002